Please enter your details to request more information

Support breakthroughs in UK diagnostic technology

  • HMRC EIS Approved investment with 30% Tax Relief
  • 885% Forecast company growth by 2028*
  • Discounted Share Offer - £1.70 Price per share offer. £12.5m Valuation
  • £85–90bn - Global cancer diagnostics market
  • £9–10bn - Liquid biopsy diagnostics market today, projected to exceed £18bn over the next decade
  • The oncology diagnostics market is growing exponentially, driven by rising cancer incidence, demand for earlier insight, and increasing adoption of repeatable diagnostic approaches.
  • 8.1m Gross profit forecast by 2028 £17.8m by 2029. £30.4m by 2030.
  • Frontier is initially focused on breast cancer, where monitoring needs are well defined and clinical pathways are established.

Frontier Diagnostics is developing a blood-based cancer diagnostic platform that enables clinicians to detect, understand, and monitor tumour behaviour using circulating tumour cells (CTCs). Suitable Investors can invest with exciting returns, and help the future of cancer care.

EIS BENEFITS FOR QUALIFYING INVESTORS INCLUDE


To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to being contacted and you consent to your data being stored in accordance with European GDPR regulations. Privacy Policy

Disclaimer: Any person accessing this website or page and considering potential investment opportunities featured here, should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This website or page should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. Suitable appropriately qualified investors, sophisticated and high net worth investors only.

*Based on Gross Profit. Download the Investment Memorandum for full Financial Forecasts.